Allergan ($AGN) may have its first Restasis competition on the way from Shire ($SHPG), which recently submitted its dry-eye candidate lifitegrast to FDA reviewers. But between Restasis' formulary coverage and market share and the new meds Allergan itself has coming up the pipeline, the Dublin drugmaker isn't worried, branded pharma chief Bill Meury told investors Monday. More from FiercePharmaMarketing